e16104 Background: Portugal has the highest gastric cancer incidence in western Europe. In our institution, FOLFIRI/XELIRI is the standard second line (2L) chemotherapy (CT) in advanced gastroesophageal adenocarcinoma (aGEA). Other treatment option is paclitaxel/ramucirumab combination. There is no prospective trial comparing these regimens. Our global aim was to investigate efficacy and safety of FOLFIRI/XELIRI after failure of a fluoropyrimidine/platinum (FP) regimen in patients with aGEA. Methods: Single center, retrospective cohort study of all patients with aGEA who failed FP regimen and received > 1 cycle of FOLFIRI/XELIRI between 2015-2020. Failure of a FP regimen defined as: 1) progression after first line (1L) palliative CT; 2) progression < 6 months after a curative intent strategy. Kaplan-Meier method was used to estimate median overall (mOS) / progression free survival (mPFS) and multivariate Cox regression analysis to assess PFS predictors. Results: Thirty-three patients analyzed. FOLFIRI/XELIRI regimen was used as 1L palliative CT (after failure of curative intent CT) in 48.5% of patients and as 2L palliative CT in 51.5%. Median age was 63 years (IQR 54–68.5), 72.7% were men. ECOG performance status (ECOG-PS) was 0-1 in 84.8%. Primary tumor site was stomach (87.9%), gastroesophageal junction (9.1%), esophagus (3.0%). All but one patient had metastatic disease (57.6% ≥2 metastatic sites; 42.4% peritoneal disease). Histology subtypes identified were diffuse and intestinal (14 patients each). Signet ring cell features were present in 12,1% of cases. 6 had HER2 positive tumors and in 1 there was microsatellite instability. 30,3% of patients had surgery of the primary tumor. Median number of cycles was 12 (IQR 5–17.5). Tumor response was accessed in 27 patients. Disease control rate was 74,1% (1 complete response, 8 partial responses, 11 stable disease). With a median follow-up of 9.4 months, mPFS was 5.1 months (95%CI 4.3-5.9) and the mOS 9.8 months (95%CI 6.6-13.0). 6-month overall survival was 69.7%. In multivariate analysis ECOG-PS (HR 6.20, p = 0.002), age (HR 0.94, p = 0.011), pre-treatment level CEA (HR 1.01, p = 0.011) and FOLFIRI/XELIRI as 1L palliative CT (HR 0.25 p = 0.004) were predictors of PFS. Treatment was discontinued in 31 patients (20 disease progression, 10 worsening of ECOG-PS). The main treatment-related grade 3 or 4 adverse events were neutropenia (12.1%), mucositis (9.1%) and anemia (6.6%). No treatment-related deaths occurred. Fifteen patients initiated a subsequent treatment line (7 taxane, 2 ramucirumab, 5 taxane/ramucirumab, 1 Tas102). Conclusions: FOLFIRI is an active and well tolerated regimen after failure of a FP regimen in patients with aGEA. Population with poor prognostic features was well represented. Efficacy outcomes were similar to the ones reported for the paclitaxel/ramucirumab combination RAINBOW trial.
This is a retrospective study of patients diagnosed with gastric cancer aged 45 years and under, treated in the Department of Medical Oncology in Blida between January 2014 and December 2017. We were interested in the clinico-epidemiological characteristics of this population.Results: During this period, 56 patients with gastric cancer aged 45 years and under were seen, which is about 25.3% of all patients with gastric cancer (total, 221 patients); 38 were male (67.8 %) and 18 were female (32.1%), the median age at diagnosis was 36 years (range, 21 to 45 years). Body mass index (BMI) was higher than 25 in 15 patients (26.7%); smoking was found in 18 patients (32.1%); consumption of salted and preserved products was observed in 23 patients (41%); a diet high in meat and fat was observed in 25 patients (44.6%); oil of cade intake was noted in some patients; family history of gastric cancer was seen in 3 patient; and a family history of other cancer was seen in 10 patients. The most common symptom was epigastralgia; diagnosis delay was >3 months in 64% of cases; the gastric antrum was the most frequent seat; the histological type was adenocarcinoma in 91%; helicobacter pylori infection was determined in 29 biopsies; locally advanced (III) and metastatic stages (IV) were identified in 35.7% and 48% of cases, respectively. Conclusion:There was a high incidence of gastric cancer in young people in our series. The main risk factors in young people are smoking, HP+, low socioeconomic status, intake of salty and smoked food, oil of cade, a diet rich in meat and fat and low in vegetables and fruits, physical inactivity, excess weight, and unknown behavioral factors. Eating habits and lifestyle factors of our young population must be analyzed carefully. Gastric cancer remains a serious health problem in Algeria; therefore, other prospective studies designed to identify other risk factors are highly recommended.
prolonged survival in chemo-refractory patients with mCRC. Here, we investigated the role of NLR as a predictive biomarker in the CAVE mCRC trial.Methods: 77 patients enrolled in the CAVE mCRC trial, treated with cetuximab rechallenge plus avelumab, were included in the current analysis. Baseline NLR was calculated and, in line with previous findings, a cut-off value of 3 was used. Plasma samples of 67 out of 77 patients were available for analysis of circulating tumor DNA (ctDNA) mutations of KRAS, NRAS, BRAF and EGFR-S492R. Correlation of NLR<3 vs NLR 3 with median overall survival (mOS), median progression-free survival (mPFS) in the intention to treat (ITT) and ctDNA RAS/BRAF/EGFR wild-type (WT) population was performed.Results: In the ITT population, mOS was 11.6 months [95% Confidence Interval (CI), 8.4-14.8 months] and mPFS was 3.6 months (95% CI, 3.2-4.1 months). Patients with a baseline NLR < 3 (38/77, 49%) had a statistically significant improvement in mOS, 17.3 months (95% CI, 14.2-20.3), compared with patients with NLR 3 (39/77, 51%) that exhibited mOS of 8.9 months (CI 95% 6.4-11.4), (HR 0.44, CI 95% 0.25-0.76, P¼ 0.004). mPFS was 3.9 months (CI 95% 2.9-4.9) in patients with NLR < 3, compared to 3.5 months (CI 95% 2.3-4.6) in patients with NLR 3 (HR 0.71, CI 95% 0.44-1.13, P¼ 0.15). In the ctDNA WT population, mOS was not reached in the NLR < 3 group (23/ 48, 48%), whereas a mOS of 8.9 months (CI 95% 6.1-11.7), (HR 0.24, CI 95% 0.10-0.58, P¼ 0.001) was reported in patients (25/48, 52%) with NLR 3. A trend towards increased mPFS was observed in NLR < 3 population [5.2 months (CI 95% 2.9-7.6) vs 3.6 months (CI 95% 2.8-4.3) (HR 0.67, CI 95% 0.36-1.23, P¼ 0.19)]. Conclusions:In the CAVE mCRC study, baseline neutrophil to lymphocyte ratio < 3 was strongly correlated with improved survival and may represent a useful biomarker to predict response to retreatment with cetuximab plus avelumab.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.